You have been consistent. You have followed your healthcare provider’s guidance on diet, exercise, and medication. And for a while, the results showed on the scale. Then it stopped. If your weight has plateaued on a GLP-1 receptor agonist at the standard maintenance dose, you are not alone — and importantly, clinical research is pointing toward a higher-dose option.
Semaglutide 7.2mg, a higher-dose formulation of the same active ingredient, has completed its clinical trial programme and demonstrated meaningful additional weight loss for patients who had reached a plateau on the standard 2.4mg maintenance dose. This article explains the science behind treatment plateaus, the STEP UP trial findings, and how higher-dose formulations may be accessed through the Health Sciences Authority (HSA) Named Patient Programme where clinically appropriate.
Why Does Weight Loss Plateau on GLP-1 Treatment?
Weight loss plateaus are a well-documented phenomenon in obesity medicine. The body has powerful homeostatic mechanisms that resist weight loss. As you lose weight, your resting metabolic rate decreases, hunger hormones like ghrelin increase, and your body becomes more efficient at storing energy. This is not a personal failure — it is biology.
For many patients on semaglutide 2.4mg, initial weight loss of 10–15% of body weight is common in the first year. However, studies show that weight loss typically reaches a plateau around week 60–68 of treatment. At this point, the 2.4mg dose has achieved what it can for your physiology, and further progress may require a different approach — which is precisely what the STEP UP trial investigated.
Understanding Higher-Dose Semaglutide (7.2mg)
Semaglutide 7.2mg is a higher-dose formulation of semaglutide, the same active ingredient found in the standard 2.4mg maintenance dose. It belongs to the GLP-1 receptor agonist class of medications, which work by mimicking the glucagon-like peptide-1 hormone that regulates appetite, slows gastric emptying, and signals satiety to the brain.
The 7.2mg dose delivers three times the amount of semaglutide compared to the standard 2.4mg maintenance dose. It is administered as a once-weekly subcutaneous injection, consistent with how lower-dose formulations are administered. The higher dose is intended for patients whose weight loss has stalled on 2.4mg and who may benefit from additional pharmacological support to continue their weight management journey.
The STEP UP Trial: Key Findings
The STEP UP trial, conducted between 1 January 2023 and 26 November 2024, was a randomised clinical trial that evaluated the efficacy and safety of semaglutide 7.2mg compared to 2.4mg and placebo. The results were significant:
- Up to 20.7% average weight loss for participants who were fully adherent to both the treatment protocol and recommended lifestyle changes
- An additional ~3% weight loss for patients whose weight had reached a plateau under semaglutide 2.4mg, demonstrating that the higher dose can overcome the treatment ceiling observed with the standard maintenance dose
- The safety profile of the 7.2mg dose was consistent with the known GLP-1 receptor agonist class, with gastrointestinal side effects being the most commonly reported
These findings are clinically meaningful. For a patient weighing 100kg, an additional 3% translates to approximately 3kg of further weight loss beyond what 2.4mg achieved — and for fully adherent patients, the total loss of 20.7% represents a transformative 20.7kg reduction from starting weight.
Who May Benefit from Higher-Dose Semaglutide?
Semaglutide 7.2mg is being studied for patients who meet both of the following criteria:
- Currently on semaglutide 2.4mg and tolerating it well — the 7.2mg dose is a step up from 2.4mg, so patients must have demonstrated good tolerance to the lower dose before considering an increase
- Weight loss has plateaued — if you have been on 2.4mg for several months and your weight has remained stable despite adherence to lifestyle modifications, you may be a candidate for dose escalation, subject to medical assessment
It is important to understand that semaglutide 7.2mg is not a first-line treatment. It is a prescription-only medication that must be initiated and supervised by a licensed doctor. A comprehensive assessment — including medical history review, physical examination, and relevant blood tests — is required before any weight management treatment is recommended.
Important: Weight management outcomes vary between individuals. The trial data reflects average results across a large study population. Your personal results will depend on factors including your starting weight, metabolic health, adherence to treatment, diet, physical activity, and other individual variables.
Access Through the HSA Named Patient Programme
Semaglutide 7.2mg has not yet received full marketing authorisation from the Health Sciences Authority (HSA) for general sale in Singapore. It may be accessible through the HSA Named Patient Programme, which allows registered medical practitioners to import unregistered therapeutic products for specific patients under their care when there is a genuine clinical need and no suitable registered alternative is available.
In the case of patients who have plateaued on semaglutide 2.4mg, the 7.2mg dose represents a clinically appropriate escalation that is not otherwise available in Singapore. The decision to pursue this pathway is made between the patient and their doctor based on individual clinical circumstances.
The Import Process: What to Expect
The overall process of importing semaglutide 7.2mg under the Named Patient Programme typically takes up to eight weeks from the point of patient registration. Here is what the timeline involves:
| Stage | Estimated Duration | What Happens |
|---|---|---|
| 1. Doctor Consultation | 1–2 days | The medical team assesses your suitability. If clinically appropriate, you are registered for the programme. |
| 2. HSA Application | 2–4 weeks | The clinic submits the Named Patient application to HSA on your behalf. |
| 3. Product Shipment | 2–3 weeks | Once HSA approval is obtained, the medication is shipped from the manufacturer to Singapore. |
| 4. Delivery to Clinic | 3–5 days | The product arrives at the clinic. You are contacted to schedule your appointment for administration under medical supervision. |
Throughout this period, you continue with your current treatment plan under your doctor’s supervision. No gap in care is required while awaiting the higher-dose formulation.
Frequently Asked Questions
Q: Is semaglutide 7.2mg safe?
The STEP UP trial found the safety profile of semaglutide 7.2mg to be consistent with the known GLP-1 receptor agonist class. The most common side effects were gastrointestinal in nature (nausea, diarrhoea, constipation). As with any prescription medication, your doctor will discuss potential risks and side effects during your consultation.
Q: Can I switch directly from 2.4mg to 7.2mg?
Dose escalation protocols are determined by your doctor based on your individual medical history and treatment response. A direct switch may not be appropriate for all patients.
Q: How much does the higher dose cost?
Costs are discussed during the consultation as they depend on the Named Patient Programme arrangement and individual treatment plan. Please speak with your doctor for details.
Q: Do I need to be an existing patient?
New patients are welcome. However, you must have a documented history of semaglutide 2.4mg use and a clinical assessment confirming suitability for the 7.2mg dose.
Q: What if I am not currently on semaglutide 2.4mg?
Semaglutide 7.2mg is specifically for patients who have plateaued on the 2.4mg dose. If you are not currently on semaglutide 2.4mg, your doctor can discuss whether medical weight management — starting with an appropriate first-line approach — is suitable for you.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Semaglutide is a prescription-only medicine. Always consult a qualified healthcare professional for medical concerns, diagnosis, or treatment. Individual results vary. NuLifeCare is an MOH-registered medical clinic in Singapore. The Named Patient Programme is administered by HSA and subject to regulatory approval.
Speak with a Doctor About Your Options
If you have been on a GLP-1 treatment and your weight loss has plateaued, the next step is to discuss your situation with a qualified medical practitioner. They can review your progress, explain the range of options available — including dose adjustments or alternative treatment approaches — and help you make an informed decision based on your individual health profile.
Every treatment decision should be guided by a doctor who understands your full medical history, current health status, and weight management goals.